PAX-D: study protocol for a randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression

Discussion Pramipexole is a promising augmentation agent for TRD and may be a useful addition to existing treatment regimes. PAX-D will assess its effectiveness and test for a potential mechanism of action in patients with TRD. Trial registration number ISRCTN84666271

http://ebmh.bmj.com/cgi/content/short/25/2/77?rss=1

Source: Evidence-Based Mental Health - April 21, 2022 Category: Psychiatry & Psychology Authors: Au-Yeung, S. K., Griffiths, J., Roberts, S., Edwards, C., Yu, L.-M., Bogacz, R., Rendell, J., Attenburrow, M.-J., Watson, S., Chan, F., Cipriani, A., Cleare, A., Harmer, C. J., Kessler, D., Evans, J., Lewis, G., Singh, I., Simon, J., Harrison, P. J., Cowe Tags: Open access Protocol Source Type: research